Shailendra Kumar, Ph.D.
Dr. Kumar serves as the Executive Vice President of Research and Development at Mellitus
leading all aspects of product development. He has nearly 30 years of experience in
academia, biotech and diagnostics industries. Previously, he served as Vice President of
Diagnostic Technologies at BOA Biomedical a portfolio company of Miraki Innovation, where
he managed sepsis diagnostics and therapeutic development, clinical studies and regulatory
activities. Dr. Kumar has a breadth of experience in developing a wide variety of IVD
platforms and diagnostic products for diseases including Covid-19, HIV, Dengue, Malaria,
Typhoid, Anthrax, Chagas, Leishmania, Clostridium difficile, UTI infections, blood
chemistry (Glucose, cholesterol, glycosylated hemoglobin, ALT, AST,
triglycerides, creatinine etc.), bladder and breast cancer. Additionally, he is
experienced in bringing IVDs to market through FDA clearance and CE marking. Prior to BOA
he was a Senior Director at Chembio Diagnostics, where he was instrumental in managing
research and development of point-of-care IVD devices for a number of infectious diseases.
Prior to Chembio, he held various roles of increasing responsibility at First Light
Diagnostics, Diagnostics For All, Matritech, Mass Diagnostics and Ranbaxy Laboratories.
Dr. Kumar received his Masters and Ph.D. in Biochemistry from Aligarh University and
Central Drug Research Institute, India. He worked as a post-doctoral fellow and instructor
at University of Illinois at Chicago and Harvard Medical School (Dana-Farber Cancer
Institute, Boston).